• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2010 - Product Image

Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2010

  • ID: 1403475
  • September 2010
  • Region: Saudi Arabia
  • 93 Pages
  • Business Monitor International

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

The Saudi Arabia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Saudi Arabia's pharmaceuticals and healthcare industry.

In BMI’s updated Business Environment Ratings (BER) for Q410, Saudi Arabia is ranked fourth out of the 19 Middle East and African markets surveyed, having dropped a place in relation to the previous quarter. Globally, it ranks 38th of the 83 countries surveyed by BMI. Saudi Arabia’s score is largely supported by the country’s wealth – and thus its preference for branded drugs – and a sizeable population, which is expected to exceed 30mn by 2014 (up from some 27mn presently).

The value of Saudi Arabia’s pharmaceutical market, calculated to be worth SAR10.39bn (US$2.77bn) at consumer prices in 2009, is forecast to post a compound annual growth rate (CAGR) of 6.52% through to 2014, when the market will reach a value of SAR14.25bn (US$3.80bn). Annual growth rates over the subsequent five years are expected to decrease under the negative READ MORE >

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Executive Summary

SWOT Analysis
Saudi Arabia Pharmaceuticals And Healthcare SWOT
Saudi Arabia Political SWOT
Saudi Arabia Economic SWOT
Saudi Arabia Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Middle East And Africa – Regional Pharmaceutical Business Environment Ratings, Q410
Rewards
Risks

Saudi Arabia – Market Summary

Regulatory Regime
Recent Regulatory Developments
Regional Regulatory Developments
Free Trade Agreements
Intellectual Property Developments
IP Deficiencies
Counterfeit Drugs
OTC Drug Market
Pricing and Reimbursement Issues
Pricing System Reform
Price Cuts
Tendering Procedures

Industry Trends and Developments

Epidemiology
Bird and Swine Influenza
HIV/AIDS
Recent Public Health Developments
Healthcare Sector
Healthcare Professionals
Primary Healthcare Provision
Secondary Healthcare Provision
Recent Healthcare Provision Developments
Health Insurance
Recent Health Insurance Developments
Pharmaceutical Distribution Sector
Table: Saudi Arabian Drug Distribution Firms
Research and Development
Medical Device Sector
Recent Medical Devices Developments

Industry Forecast Scenario

Pharmaceutical Market Forecast
Key Growth Factors – Industry
Key Growth Factors – Macroeconomic
Table: Saudi Arabia - Economic Activity, 2007-2014
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Medical Device Market Forecast
Pharmaceutical Trade Forecast
Other Healthcare Data Forecasts
Key Risks to BMI Forecasts

Competitive Landscape

Pharmaceutical Industry
Table: Saudi Arabia – Leading Pharmaceutical Companies by Sales
Foreign Industry
Domestic Industry
Recent Pharmaceutical Company Developments

Company Profiles

Indigenous Company Profiles
Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO)
Saudi Arabian Japanese Pharmaceutical (SAJA)
TABUK Pharmaceutical Manufacturing
Al Jazeera Pharmaceutical Industries (JPI)
Multinational Company Profiles
GlaxoSmithKline
Novartis
Merck & Co
Pfizer
Sanofi-Aventis

Country Snapshot: Saudi Arabia Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2003-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 1999-2006
Table: Consumer Expenditure, 2000-2012 (US$)

BMI Methodology

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceuticals Business Environment Ratings

Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

Forecast Tables

- Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO)
- Saudi Arabian Japanese Pharmaceutical (SAJA)
- TABUK Pharmaceutical Manufacturing
- Al Jazeera Pharmaceutical Industries (JPI)
- GlaxoSmithKline
- Novartis
- Merck & Co
- Pfizer
- Sanofi-Aventis

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos